Truist analyst Jailendra Singh raised the firm's price target on Phreesia to $31 from $29 and keeps a Buy rating on the shares. The analyst cites the company's "solid" Q2 results and raised FY25 EBITDA outlook, adding that based on the management's preliminary guidance on some operational metrics for FY26 and the firm's follow-up conversations, the reasonable starting point for top-line growth expectations is relatively closer to mid-teens.